Physician profile
Ryan J Smith
NPI 1376980318
$12,477.93
in general payments reported to CMS, 2019-2025
25 companies · $4,531 in 2025
The $4,531 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $419 · 2021: $3,221 · 2022: $919 · 2023: $1,509 · 2024: $1,341 · 2025: $4,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005 · Consulting Fee: $3,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.22 |
| Consulting Fee | $3,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $4,181.95 | 2021-2025 | Idosetr, Idose, Radius |
| Alcon Vision LLC | $2,413.61 | 2019-2025 | Hydrus Microstent, Clareon, Wavelight Ex500 Excimer Laser |
| Ivantis, INC | $2,222.27 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $825.61 | 2021-2025 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Abbvie INC. | $645.08 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Novartis Pharmaceuticals Corporation | $564.28 | 2019-2023 | |
| Allergan, INC. | $279.42 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $212.31 | 2022-2025 | Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $160.21 | 2019-2021 | |
| Ellexiscience | $143.91 | 2019 | |
| Rxsight INC | $130.65 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Regeneron Healthcare Solutions, INC. | $111.27 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.54 | 2019-2021 | |
| Beaver-Visitec International, INC. | $91.81 | 2023-2025 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $79.07 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma, INC. | $65.93 | 2025 | Koate, Albuked, Kedrab |
| Ocular Therapeutix, INC. | $57.42 | 2024-2025 | Dextenza |
| Alcon Research LLC | $38.35 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $30.33 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $27.85 | 2019 | |
| Horizon Therapeutics Plc | $24.26 | 2021 | |
| Astellas Pharma US INC | $21.61 | 2025 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $14.02 | 2025 | |
| Lensar, INC. | $9.77 | 2024 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.